Estradiol and Progesterone
AssetAlso Estrogens, Progestins, BIJUVA, BIJUVATM
Hormone replacement therapy activating estrogen and progesterone nuclear receptors to manage menopausal symptoms.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- ESR1
- 1
- Indication
- 47
- Trials
- 3
- Developers
Indications
1Menopause
Phase 3, Completed, NCT01942668, clinicaltrials.gov, Oct 18, 2026
In the full profile
- Targets and what it contains5
- Owner and partners6
- Trials47
- Evidence for its targets5
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.